Phase I trial of temozolomide plus O(6)-benzylguanine 5-day regimen with recurrent malignant glioma

This phase I clinical trial conducted with patients who had recurrent or progressive malignant glioma (MG) was designed to determine the maximum tolerated dose (MTD) and toxicity of three different 5-day dosing regimens of temozolomide (TMZ) in combination with O(6)-benzylguanine (O(6)-BG). Both TMZ...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Quinn, Jennifer A., Jiang, Sara Xiaoyin, Reardon, David A., Desjardins, Annick, Vredenburgh, James J., Rich, Jeremy N., Gururangan, Sridharan, Friedman, Allan H., Bigner, Darell D., Sampson, John H., McLendon, Roger E., Herndon, James E., Walker, Amy, Friedman, Henry S.
Formato: Artigo
Idioma:Inglês
Publicado em: Duke University Press 2009
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2765345/
https://ncbi.nlm.nih.gov/pubmed/19289491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1215/15228517-2009-007
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados